These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 25883042

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM.
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
    Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC.
    J Clin Oncol; 2014 Dec 20; 32(36):4134-40. PubMed ID: 25385737
    [Abstract] [Full Text] [Related]

  • 7. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.
    J Clin Oncol; 2011 Jun 20; 29(18):2493-8. PubMed ID: 21576633
    [Abstract] [Full Text] [Related]

  • 8. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ.
    Ann Pharmacother; 2015 Sep 20; 49(9):1057-67. PubMed ID: 26041811
    [Abstract] [Full Text] [Related]

  • 9. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS, Gökbuget N, Zugmaier G, Stein AS, Dombret H, Chen Y, Ribera JM, Bargou RC, Horst HA, Kantarjian HM.
    Cancer; 2021 Feb 15; 127(4):554-559. PubMed ID: 33141929
    [Abstract] [Full Text] [Related]

  • 10. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S.
    Clin Pharmacokinet; 2016 Oct 15; 55(10):1271-1288. PubMed ID: 27209293
    [Abstract] [Full Text] [Related]

  • 11. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C, Thomas X.
    Drug Des Devel Ther; 2016 Oct 15; 10():757-65. PubMed ID: 26937176
    [Abstract] [Full Text] [Related]

  • 12. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
    Wolach O, Stone RM.
    Clin Cancer Res; 2015 Oct 01; 21(19):4262-9. PubMed ID: 26283683
    [Abstract] [Full Text] [Related]

  • 13. [Cancer therapy using bispecific antibodies].
    Kadowaki N.
    Rinsho Ketsueki; 2018 Oct 01; 59(10):1942-1947. PubMed ID: 30305495
    [Abstract] [Full Text] [Related]

  • 14. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J, Mace M, Kantarjian H, Jabbour E.
    Drugs Today (Barc); 2015 Apr 01; 51(4):231-41. PubMed ID: 26020065
    [Abstract] [Full Text] [Related]

  • 15. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.
    Leukemia; 2017 Apr 01; 31(4):777-787. PubMed ID: 28028314
    [Abstract] [Full Text] [Related]

  • 16. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J, Benjamin J, Nagorsen D.
    Expert Opin Biol Ther; 2015 Apr 01; 15(8):1093-9. PubMed ID: 25971805
    [Abstract] [Full Text] [Related]

  • 17. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A, Locatelli F, Stieglmaier J, Zaman F, Jabbour E.
    Ann Hematol; 2020 Oct 01; 99(10):2215-2229. PubMed ID: 32856140
    [Abstract] [Full Text] [Related]

  • 18. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C, Lalayanni C, Iskas M, Douka V, Pastelli N, Anagnostopoulos A.
    Curr Probl Cancer; 2019 Jun 01; 43(3):222-227. PubMed ID: 29895435
    [Abstract] [Full Text] [Related]

  • 19. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
    Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM.
    Cancer; 2020 Jul 15; 126(14):3192-3201. PubMed ID: 32401342
    [Abstract] [Full Text] [Related]

  • 20. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC, Gökbuget N.
    Expert Opin Drug Saf; 2017 Oct 15; 16(10):1191-1202. PubMed ID: 28825327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.